Allergan settles Restasis litigation with Famy Care

Pharmaceutical giant Allergan announced it reached a settlement regarding its litigation with Famy Care Limited relating to six Allergan US patents covering dry eye drug Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%.

The patents are listed in the Orange Book and expire on August 27, 2024.

“As a result of the settlement, all Famy Care litigation regarding Restasis patents will be dismissed and Famy Care will terminate its pending petitions for Inter Parties Review,” said Allergan.

“Allergan will grant Famy Care a license to market a generic version of Restasis in the United States beginning on February 27, 2024, or earlier under certain circumstances.”

Additional details regarding the settlement were not disclosed.